KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 10 years, with Q4 2025 value amounting to $267.7 million.

  • Alnylam Pharmaceuticals' Other Operating Expenses rose 16038.79% to $267.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $681.9 million, marking a year-over-year increase of 11086.4%. This contributed to the annual value of $681.9 million for FY2025, which is 11086.4% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Other Operating Expenses stood at $267.7 million, which was up 16038.79% from $200.2 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Operating Expenses registered a high of $267.7 million during Q4 2025, and its lowest value of $31.1 million during Q1 2021.
  • Its 5-year average for Other Operating Expenses is $81.2 million, with a median of $67.3 million in 2024.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Other Operating Expenses crashed by 1955.96% in 2024, and later skyrocketed by 16038.79% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Other Operating Expenses stood at $37.7 million in 2021, then soared by 36.11% to $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then rose by 19.75% to $102.8 million in 2024, then soared by 160.39% to $267.7 million in 2025.
  • Its last three reported values are $267.7 million in Q4 2025, $200.2 million for Q3 2025, and $143.0 million during Q2 2025.